ODAC Votes in Favor of Continued Development of Dostarlimab for dMMR/MSI-H Locally Advanced Rectal Cancer

The FDA’s ODAC voted that data from two proposed single-arm trials will provide adequate means of characterizing the risk-benefit profile of dostarlimab.